May 27, 2017
1 min read

Dana-Farber Cancer Institute appoints gastrointestinal cancer center director

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Brian Wolpin, MD, MPH, has been appointed director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute.

Wolpin is chair in pancreatic cancer at Dana-Farber, as well as associate professor of medicine at Harvard Medical School. He also has served as co-director of the Pancreas and Biliary Tumor Center at Dana-Farber/Brigham and Women’s Cancer Center.

Brian Wolpin

“Dr. Wolpin has been a highly sought-after clinician focused on the treatment of patients with pancreatic cancer,” Laurie H. Glimcher, MD, president and CEO of Dana-Farber, said in a press release. “He has made important contributions to the field of pancreatic cancer research, translating discoveries into new strategies for early detection and treatment. Through his clinical and research work, he has demonstrated the leadership skills that made him an ideal choice for this position.”

In his new role, Wolpin will guide the center as it strives to deliver high-quality clinical care and research. He also will oversee translational research programs and the center’s educational mission. Wolpin succeeds Charles Fuchs, MD, MPH.

“I am extremely honored to serve as the director of the Gastrointestinal Cancer Center at Dana-Farber,” Wolpin said in the release. “With an incredibly talented and dedicated team of researchers and clinicians, the Center is making ground-breaking discoveries while delivering cutting-edge, compassionate care to all patients with gastrointestinal cancers.”